Misuse
of Drugs (Miscellaneous Amendments) (No. 5)
(Jersey) Order 2014
Made 2nd July 2014
Coming into force 9th July 2014
THE MINISTER FOR HEALTH AND SOCIAL SERVICES, in pursuance of Articles 3,
12, 13 and 27 of the Misuse of Drugs (Jersey) Law 1978[1], and on the recommendation of the
Advisory Council on the Misuse of Drugs, orders as follows –
1 Misuse of Drugs (Jersey) Law 1978
amended
In the Misuse of Drugs (Jersey) Law 1978[2] –
(a) in
Part 1 of Schedule 2, in paragraph 1 –
(i) for
the full stop at the end of sub-paragraph (e) there is substituted a
semi-colon, and
(ii) after
sub-paragraph (e) there is added the following sub-paragraph –
“(f) any compound (not being benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine)
structurally derived from mescaline, 4-bromo-2,5-dimethoxy-α-methylphenethylamine, 2, 5-dimethoxy-α,4-dimethylphenethylamine,
N-hydroxytenamphetamine, or a compound specified in
sub-paragraph (a) or (c), by substitution at the nitrogen atom of the amino
group with a benzyl substituent, whether or not substituted in the phenyl ring
of the benzyl group to any extent.”;
(b) in
Part 2 of Schedule 2 –
(i) in
paragraph 1(a) –
(A) after the substance
“Glutethimide” there is inserted the substance “Ketamine”,
(B) after the
substance “N-adamantyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135)”
there are inserted the following substances –
“N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
(5F-AB-PINACA)
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
(AB-FUBINACA)”, and
(C) after the
substance “Quinolin-8-yl-1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22)”
there are inserted the following substances –
“Quinolin-8-yl-1-(cyclohexylmethyl)-1H-indole-3-carboxylate (BB-22)
Quinolin-8-yl-1-pentyl-1H-indole-3-carboxylate
(PB-22)”,
(ii) for
paragraph 1(j) there is substituted the following sub-paragraph –
“(j) any compound (not being a compound specified in paragraph 1(a)
of Part 1) structurally derived from 1-benzofuran, 2, 3-dihydro-1-benzofuran,
1H-indole, indoline, 1H-indene, or indane by substitution in the 6-membered ring with a
2-ethylamino substituent whether or not further substituted in the ring system
to any extent with alkyl, alkoxy, halide or haloalkyl substituents and whether
or not substituted in the ethylamino side -chain with one or more alkyl
substituents;”;
(c) in
Part 3 of Schedule 2, in paragraph 1(a) –
(i) after
the substance “Ethyl loflazepate” there is inserted the substance “Etizolam”,
(ii) the
substance “Ketamine” is deleted,
(iii) after
the substance “Ketazolam” there is inserted the substance “Khat”,
(iv) after
the substance “Triazolam” there is inserted the substance “Zaleplon”,
and
(v) after
the substance “Zolpidem” there is inserted the substance “Zopiclone”;
(d) in
Part 4 of Schedule 2, after the definition of the expression
“concentrate of poppy-straw” there is inserted the following expression and
definition –
“ ‘Khat’ means the leaves, stems or shoots of the plant of the species Catha edulis;”.
2 Misuse of Drugs
(Designation) (Jersey) Order 1989 amended
In Part 1 of the Schedule to the Misuse of Drugs
(Designation) (Jersey) Order 1989[3] –
(a) in
paragraph 1(a) –
(i) after
the substance “4-hydroxybutanoic acid
(4-hydroxy-n-butyric acid; gamma-hydroxybutyric acid)” there is inserted the
substance “Khat”,
(ii) after the substance “N-adamantyl-1(5-fluoropentyl)-1H-indole-3-carboxamide
(STS-135)” there are inserted the following substances –
“N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
(5F-AB-PINACA)
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
(AB-FUBINACA)”, and
(iii) after the substance
“Quinolin-8-yl-1-(5fluoropentyl)-1H-indole-3-carboxylate (5F-pB-22)” there are
inserted the following substances –
“Quinolin-8-yl-1-(cyclohexylmethyl)-1H-indole-3-carboxylate (BB-22)
Quinolin-8-yl-1-pentyl-1H-indole-3-carboxylate
(PB-22)”;
(b) after paragraph 1(g) there are inserted the following
sub-paragraphs –
“(ga) any compound (not being a compound specified in sub-paragraph (a))
structurally derived from 1-benzofuran, 2, 3-dihydro-1-benzofuran, 1H-indole, indoline, 1H-indene, or indane by
substitution in the 6-membered ring with a 2-ethylamino substituent whether or
not further substituted in the ring system to any extent with alkyl, alkoxy,
halide or haloalkyl substituents and whether or not substituted in the
ethylamino side -chain with one or more alkyl substituents;
(gb) any compound (not being benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine)
structurally derived from mescaline, 4-bromo-2, 5-dimethoxy-α-methylphenethylamine, 2, 5-dimethoxy-α,4-dimethylphenethylamine, N-hydroxytenamphetamine, or a compound specified in sub-paragraph
(a) or (c), by substitution at the nitrogen atom of the amino group with a
benzyl substituent, whether or not substituted in the phenyl ring of the benzyl
group to any extent;”.
3 Misuse of Drugs
(General Provisions) (Jersey) Order 2009 amended
In the Misuse of Drugs (General Provisions)
(Jersey) Order 2009[4] –
(a) in
paragraph 1(a) of Schedule 1 –
(i) after
the substance “Etryptamine” there is inserted the substance “Khat”,
(ii) after
the substance “N-adamantyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135)”
there are inserted the following substances –
“N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-AB-PINACA)
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
(AB-FUBINACA)”, and
(iii) after
the substance “Quinolin-8-yl-1-(5-fluoropentyl)-1H-indole-3-carboxylate
(5F-PB-22)” there are inserted the following substances –
“Quinolin-8-yl-1-(cyclohexylmethyl)-1H-indole-3-carboxylate (BB-22)
Quinolin-8-yl-1-pentyl-1H-indole-3-carboxylate
(PB-22)”;
(b) after
paragraph 1(f) of Schedule 1 there is inserted the following
sub-paragraph –
“(fa) any compound (not being benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine)
structurally derived from mescaline, 4-bromo-2, 5-dimethoxy-α-methylphenethylamine, 2, 5-dimethoxy-α,4-dimethylphenethylamine,
N-hydroxytenamphetamine, or a compound specified in
sub-paragraph (c) or (d), by substitution at the nitrogen atom of the
amino group with a benzyl substituent, whether or not substituted in the phenyl
ring of the benzyl group to any extent;”;
(c) for
paragraph 1(t) of Schedule 1 there is substituted the following
sub-paragraph –
“(t) any compound (not being a compound specified in sub-paragraph (c))
structurally derived from 1-benzofuran, 2, 3-dihydro-1-benzofuran, 1H-indole, indoline, 1H-indene, or indane by
substitution in the 6-membered ring with a 2-ethylamino substituent whether or
not further substituted in the ring system to any extent with alkyl, alkoxy,
halide or haloalkyl substituents and whether or not substituted in the
ethylamino side -chain with one or more alkyl substituents;”;
(d) in
Schedule 2, in paragraph 1 after the substance “Isomethadone” there
is inserted the substance “Ketamine”;
(e) in
Schedule 4, in paragraph 1 –
(i) after
the substance “Ethyl loflazepate” there is inserted
the substance “Etizolam”,
(ii) the
substance “Ketamine” is deleted,
(iii) after
the substance “Triazolam” there is inserted the substance “Zaleplon”, and
(iv) after
the substance “Zolpidem” there is inserted the substance “Zopiclone”.
4 Citation and commencement
This Order may be cited as
the Misuse of Drugs (Miscellaneous Amendments) (No. 5) (Jersey) Order 2014
and shall come into force 7 days after it is made.
deputy a.e. pryke of trinity
Minister for Health and
Social Services